Navigation Links
US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results
Date:2/28/2008

RECONCILIATION OF NET INCOME (LOSS) TO EBITDA AND ADJUSTED EBITDA

(in thousands)

(unaudited)

Three Months Three Months

Ended Ended Year Ended

December 31, September 30, December 31,

2007 2006 2007 2007 2006

Net income (loss) $(14,830) $3,253 $(4,194) $(34,973) $26,158

Add back:

Interest expense,

net 36,913 29,547 34,414 137,496 117,088

Income tax

(benefit)

provision (7,869) 3,654 (4,760) (17,447) 18,926

Depreciation and

amortization 23,456 21,660 23,239 89,331 83,334

Amortization of

stock compensation 277 746 15 753 2,149

Minority interest

expense 1,743 660 539 3,619 2,388

Other expense 11,573 - 312 11,885 -

EBITDA 51,263 59,520 49,565 190,664 250,043

Plus:

Loss on

extinguishment

of debt - - - 12,917 -

Impairment and

restructuring

charges 6,771 - 960 15,126 -

Adjusted EBITDA 58,034(1) 59,520(1) 50,525(1) 218,707(1) 250,043(1)

Changes in assets

and liabilities 45,954 29,394 (14,787) 77,708 (97,934)

Deferred income

tax provision

(benefit) (699) 1,414 (10,017) (11,689) 4,422

Interest

expense, net (36,913) (29,547) (34,414) (137,496) (117,088)

Income tax

benefit

(provision) 7,869 (3,654) 4,760 17,447
'/>"/>

SOURCE US Oncology Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26

Related biology technology :

1. Six UK Hospitals Join Together in Using Varian Medical Oncology Information Network
2. Genstruct CEO, Dr. Keith Elliston, Invited to Speak at Oncology Clinical Trial Summit
3. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
4. Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology
5. Pharsight Invited to Present on Oncology Modeling and Simulation at Quantitative Pharmacology Symposium in China
6. PRA International to Present Audioconference on Oncology Research - Nov. 8
7. IMPAC Medical Systems to Offer Revenue Cycle Inc.s Array of Oncology Products and Services to Customers
8. AG Mednet to Provide Image Network for Southwest Oncology Group
9. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
10. Center for Molecular Medicine Selected to Provide DNA Analysis for Childrens Oncology Group Leukemia Study
11. Oncology Metrics and Cureline Announce Joint Marketing Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 2014 “Our nation's healthcare system ... national disgrace. Furthermore, every governmental and professional entity ... deplorable state of unorganized dysfunction shares in that ... merely serve as a device to use in ... failure(s) that have accumulated through the years leading ...
(Date:8/21/2014)... 21, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... in class collagenase-based products marketed as XIAFLEX ® ... U.S. and XIAPEX ® in the EU, ... randomized, double-blind Phase 2a study of CCH for ... panniculopathy. The results showed that all three doses ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 DNA vaccine ... progress in its development of JRC-LAMP-vax, an innovative and ... pollen. Phase IC studies began this month in Hawaii, ... hay fever. , The Japanese red cedar releases pollen ... in Japan. Mountain Cedar pollen wreaks similar havoc in ...
(Date:8/21/2014)... Finnish-Swedish research group at the Institute for Molecular ... institutet, Stockholm, has developed a novel "man and ... This innovative diagnostic aid was described in ... The method is based on computer vision algorithms ... combined with visualization of only the diagnostically most ...
Breaking Biology Technology:5 Great Mistakes in Healthcare and How to Fix Them by Dr. Ira Williams 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4A novel 'man and machine' decision support system makes malaria diagnostics more effective 2
... uses Medical College of Wisconsin technologies and clinical and ... of diagnostics for sepsis and pneumonia. , ,The company, ... will come over the next five years, would enable ... methods, and demonstrate the performance of this new molecular ...
... Brady Corp., a Milwaukee-based identification, safety, graphic systems ... security software developer. , ,Brady did not disclose ... , of San Jose. , ,STOPware, founded in ... and track visitors in a variety of settings, including ...
... Madison, Wis. -- Dr. Carlos Perez has been ... Inc . in Madison. Perez is a former president ... more than 40 years of experience in radiation oncology. ... of Radiation Oncology at Mallinckrodt Institute of Radiology, Siteman ...
Cached Biology Technology:
(Date:8/22/2014)... consumers will finally be able to purchase fuel cell ... zero-emissions vehicles, most of the cars will run on ... contributes to global warming. , Now scientists at Stanford ... an ordinary AAA battery to produce hydrogen by water ... two electrodes that split liquid water into hydrogen and ...
(Date:8/22/2014)... heard of the birds and the bees. But ... are being fertilized. The fertilization process for flowering ... between the male and female reproductive cells. New ... Heidelberg, and Munich, and including Carnegie,s Wolf Frommer, ... the chemical signaling process that guides flowering plant ...
(Date:8/21/2014)... including researchers from the University of Georgia recently published the ... journal Science . Their discovery paves the way for ... farming and industry. , Canola is grown across much ... is increasingly cultivated in Georgia. Canola oil used for cooking ... and rich supply of omega-3 fatty acids, but the plant ...
Breaking Biology News(10 mins):Stanford scientists develop a water splitter that runs on an ordinary AAA battery 2Stanford scientists develop a water splitter that runs on an ordinary AAA battery 3Calcium and reproduction go together 2Canola genome sequence reveals evolutionary 'love triangle' 2
... The Field Museum announced today that it has received 409,416 ... of Monaco Foundation for a three-year project: Establishing new conservation ... biological inventories by The Field Museum,s Environment, Culture, and Conservation ... landscapes in Ecuador, Peru, and Bolivia. Eight of these areas ...
... CryoLife, Inc. (NYSE: CRY) Elite cardiovascular surgeons from around ... the two-day Ross Summit to review and discuss current peer-reviewed ... and to practice the technical nuances required to perform this ... type of specialized aortic valve surgery in which the patient,s ...
... Rush University Medical Center is participating in a ... to determine whether a vitamin-like substance, in high doses, ... disorder that affects about one million people in the ... we have for Parkinson,s can only mask the symptoms ...
Cached Biology News:Prince Albert II of Monaco Foundation helps fund Field Museum conservation efforts in Peru 2Growing outcomes evidence spurs renewed interest in unique heart valve procedure 2Can an over-the-counter vitamin-like substance slow the progression of Parkinson's disease? 2
Mouse monoclonal antibody raised against a full length recombinant SCGB3A2. NCBI Entrez Gene ID = SCGB3A2...
Mouse polyclonal antibody to BAG2 - BCL2-associated athanogene 2...
Mouse monoclonal antibody raised against a partial recombinant QPCT. NCBI Entrez Gene ID = QPCT...
Mouse monoclonal antibody raised against a partial recombinant CENTB2. NCBI Entrez Gene ID = CENTB2...
Biology Products: